TriSalus Life Sciences grants CFO Sean Murphy option for 125,000 shares at $9.28

TriSalus Life Sciences, Inc.

Granted on Jan 24, 2024, under the 2023 Equity Incentive Plan.
Exercise price of $9.28 per share, equal to grant-date market price.
Vests 25% on first anniversary, remaining 75% in 36 equal monthly installments.
Contingent on Mr. Murphy's continuous service through each vesting date.
Award recognizes CFO's 2023 performance and aligns long-term incentives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.